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By  
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University of Nebraska Medical Center, 2017 
 
ABSTRACT 
BACKGROUND: Bone health is a serious concern for long-term survivors of Allo-HSCT 
due to multiple risk factors including steroids, chemotherapy, immunosuppressive 
drugs, and poor nutrition status1. Steroids have been long proven to have negative 
impact on bone health and the National Osteoporosis Foundation (NOF) lists steroids as 
a contributing factor to osteoporosis and fractures. NOF guidelines recommend 
providing adequate daily vitamin D as a safe and inexpensive way to help reduce 
fracture risk1. Therefore, proper supplementation of vitamin D may increase the quality 
of life for patients post Allo-HSCT.  
PURPOSE: The purpose of this study is to determine if Allo-HSCT patients who receive 
steroids as part of their treatment at Nebraska Medicine are being supplemented with 
vitamin D. 
METHODS: A retrospective review of electronic medical records was used to determine 
if vitamin D supplementation was prescribed to patients who received steroids after 
undergoing Allo-HSCT and whether this had an impact on their bone health, including 
serum 25(OH)D levels, incidence of fractures/falls, DEXA scan results, and GVHD 
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diagnosis. Inclusion criteria included adults who received Allo-HSCT from January 1, 
2013 to December 31, 2014.  
RESULTS: Out of 99 patients who underwent Allo-HSCT, 59 percent were prescribed 
steroids of > 5 mg/day of prednisone or equivalent for > 3 months, compared to 41 
percent who were not. Vitamin D supplementation was significantly different between 
the two groups with 71 percent of the steroid group receiving vitamin D 
supplementation compared to 40 percent of the non-steroid group (p=0.004). Diagnosis 
of GVHD was also found to be statistically significant between groups with 90 percent of 
the steroid group compared to 71 percent of the non-steroid group (p=0.016). Mortality 
was found to be significantly higher in the non-steroid group compared to the steroid 
group (p=0.005). 
CONCLUSION: This study found 71 percent of patients who received steroids of > 5 
mg/day of prednisone or equivalent for > 3 months, received vitamin D 
supplementation. However, adequacy of vitamin D supplementation is still uncertain in 
this patient population. 
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CHAPTER 1: INTRODUCTION 
Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) is a proven 
treatment for those suffering from malignant hematologic diseases of the blood or bone 
marrow such as acute myeloid leukemia or myelodysplastic syndrome. Allo-HSCT 
involves the transfer of stem cells from the donor to recipient, after their immune 
systems have been wiped out by chemotherapy, radiation, or a combination of both. 
The most significant risk of undergoing Allo-HSCT is the development of graft-versus-
host disease (GVHD). Studies have been conducted to evaluate supplementation of 
vitamin D and improved survival rate of certain cancers and decreased risk of 
developing GVHD2,3. However, there are few studies which evaluate supplementation of 
vitamin D related to the use of steroids during Allo-HSCT. Steroids are proven to have 
negative effects on the metabolism vitamin D, including inhibition of osteoblast 
function, enhancement of bone resorption, inhibition of gastrointestinal calcium 
absorption, and increase in urine calcium loss. To treat vitamin D deficiency, NOF 
recommends adults be treated with 50,000 IU of vitamin D once a week or the 
equivalent daily dose (7,000 IU vitamin D2 or vitamin D3 daily) for 8-12 weeks to achieve 
normal (> 30 ng/mL) serum 25(OH)D concentrations1. Overall, the nutrition status of 
patients who undergo Allo-HSCT is extremely complex and unstable. For those patients 
who are treated with steroids, it is important to prevent further deterioration of their 
health and functional status by adequately supplementing vitamin D to ensure adequate 
25(OH)D levels. 
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CHAPTER 2: LITERATURE REVIEW 
Vitamin D 
Vitamin D is often categorized as a fat-soluble vitamin; however, it is not an 
essential dietary factor as humans can produce it endogenously4. More accurately, 
vitamin D is closely related to a steroid hormone due to its molecular structure. Vitamin 
D consists of two bioequivalent forms (ergocalciferol and cholecalciferol) both of which 
are biologically inert until metabolized in the body5. Ergocalciferol (vitamin D2) is 
obtained from dietary vegetable sources and oral supplements. Cholecalciferol (vitamin 
D3) is obtained in fortified foods and oral supplements, but primarily through skin 
exposure to ultraviolet B radiation in sunlight5. The skin produces vitamin D3 
photochemically from 7-dehydrocholesterol, which is then metabolized in the liver to 
produce 25-hydroxycholecalciferol (25[OH]D). Within the kidneys, 25(OH)D serves as a 
substrate for 1-alpha-hydroxylase to make 1,25-dihydroxycholecalciferaol (1,25[OH]2D), 
the biologically active form4. The biologically active form then has a significant role in 
bone health. 1,25(OH)2D stimulates the absorption of calcium and phosphate from the 
gut by opening calcium channels and stimulating the formation of calcium binding 
proteins6. If 1,25(OH)2D concentrations drop due to deficiencies, less calcium is available 
for bone mineralization. Parathyroid hormone (PTH) will then increase, stimulating the 
hydroxylation of 25(OH)D in the kidney to produce more 1,25(OH)2D. This increase in 
PTH stimulates bone turnover and loss6. Therefore, vitamin D deficiency is known to 
cause high bone turnover leading to osteoporosis, osteomalacia, falls and fractures. 
(Figure 1) 
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Figure 1: Pathophysiologic pathways from vitamin D deficiency to osteoporosis, osteomalacia, 
falls and fractures.6 
In the Longitudinal Aging Study Amsterdam (LASA) study which looked at serum 
25(OH)D influences on serum PTH and parameters of bone health, serum osteocalcin 
(maker for bone formation) and urinary deoxypyridinolin excretion (marker of bone 
resorption), were shown to be elevated when serum 25(OHD) was low.  Both markers 
were shown to decrease with a rise in serum 25(OH)D levels up to 40 nmol/L (16.03 
ng/dL)7. A placebo-controlled trial of 330 older women found a serum 25(OH)D level of 
10 nmol/l (4 ng/mL) resulted in a risk ratio (RR) of hip fracture of 1.88. In a global study 
of 7,441 postmenopausal women with osteoporosis there was a significant positive 
relationship between serum 25(OH)D and bone mineral density (BMD) in the 
trochanteric area of the hip, threshold below 50 nmol/L9. 
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High bone turnover can then lead to increased risk of falls and fractures. 
Epidemiological studies show a relationship between vitamin D deficiency and fractures. 
In the LASA study incidence of fractures was higher when serum 25(OH)D was lower 
than 30 nmol/L (12.01 ng/mL), and the lowest percentage of fractures was found with 
serum 25(OH)D above 75 nmol/L (30 ng/mL)10. In the Women’s Health Initiative study, 
all women were treated with 1500mg/day of calcium citrate and 1000 IU/day of vitamin 
D3 for 6 weeks11. The purpose of this study was to examine the effect of short term 
calcium and vitamin D supplementation on biochemical markers of bone turnover. Their 
analysis showed a significant decrease of hip fracture incidence and hip bone density 
was found to be 1.06 percent higher in the calcium plus vitamin D group than in the 
placebo (p<0.01)11. 
Assessing Vitamin D 
To determine vitamin D levels within the body, serum 25(OH)D concentrations 
are assessed as the active form of vitamin D is physiologically regulated. 25(OH)D is the 
key substrate for 1-alpha-hydroxylase to produce 1,25(OH)2D. Therefore, production of 
1,25(OH)2D is directly dependent on the absolute concentrations of 25(OH)D. Currently 
there is debate among research regarding adequate levels of serum 25(OH)D levels. 
According to the Institute of Medicine, serum 25(OH)D levels of 20 ng/mL is considered 
adequate for most individuals9. However, the Endocrine Society, International 
Osteoporosis Foundation, American Geriatric Society, and NOF suggest a minimum level 
of 30 ng/mL1,13-15. The debate regarding adequate serum 25(OH)D concentrations is 
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based on adequate suppression of PTH concentrations to ensure intestinal absorption of 
calcium does not lead to a decrease in serum calcium. In a prospective study of serum 
25(OH)D level it was found baseline 25(OH)D levels were inversely associated with all-
cause mortality risk (adjusted hazard ratio [HR] = 0.95, 95% CI=0.92-0.98, per 10 nmol/L 
[4 ng/mL] of 25[0H]D)16. 
Vitamin D Supplementation 
Vitamin D supplementation comes in two forms, ergocalciferol (vitamin D2) and 
cholecalciferol (Vitamin D3). Vitamin D3 is the most efficient form of supplementation 
as it has greater affinity for the vitamin D-binding protein and has a longer half-life (~3 
weeks) compared to that of vitamin D2, therefore less frequent dosing may be 
required18. In a meta-analysis of seven randomized control trials evaluating serum 
25(OH)D concentrations after supplementation with vitamin D3 versus vitamin D2, 
vitamin D3 was shown to increase serum 25(OH)D levels more efficiently (p=0.001)19. 
However, at this time the NOF recommends either form of supplementation to reach 
adequate serum 25(OH)D levels. The NOF recommends vitamin D intake for adults age 
50 and older of 800-1000 IU per day, including supplementation if necessary1. If a 
patient is diagnosed with vitamin D deficiency (VDD) the NOF recommends adults be 
treated with 50,000 IU of vitamin D once a week or the equivalent daily dose (7,000 IU 
vitamin D2 or vitamin D3 daily) for 8-12 weeks to achieve serum 25(OH)D level of 30 
ng/mL1. After this level is reached NOF recommends maintenance therapy to preserve 
those concentrations1. However, determining adequate dosing should be individualized 
based on a multitude of factors such as baseline serum 25(OH)D, absorptive capacity, 
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and ability of liver to convert metabolites20. Therefore, Allo-HSCT patients likely require 
higher dosages due to their multiple risk factors and complex health status. Regardless 
of specific units of vitamin D supplementation, NOF and ACR guidelines, recommend 
supplementing enough vitamin D to maintain adequate serum 25(OH)D levels, whatever 
amount that may be1,17. Although severe vitamin D deficiencies are uncommon, the 
2005-2006 NHANES study reported subclinical vitamin D deficiencies (defined as < 20 
ng/mL) in 41.6% of their adult participants21. For generalized healthy adults, VDD may 
not have any severe signs and symptoms, but for those who are undergoing treatment 
for cancer, VDD may have more of an effect on their overall outcomes. 
Vitamin D and Cancer 
Research regarding vitamin D status and cancer has become of more interest in 
recent years, with the potential role of vitamin D as an easily modifiable mediator of a 
broad array of pathologic conditions, including cancer22. In a prospective study which 
looked at vitamin D status and cancer incidence in men, an increment of 25nmol/L (10 
ng/mL) in predicted 25(OH)D level was associated with a 17% reduction in total cancer 
incident (RR=0.83, 95% CI 0.74-0.92), a 29% reduction in total cancer mortality (RR=0.71, 
95% CI 0.60-0.83), and a 45% reduction in digestive-system cancer mortality (RR=0.55, 
95% CI 0.41-0.74)23. Another study looked at association between total average annual 
sunlight and age-adjust breast cancer mortality rates in 87 regions of the U.S. Risk of 
fatal breast cancer in the major urban areas of the U.S. was inversely proportional to 
intensity of local sunlight (r=0.82, p=0.0001)24. In addition, a study which looked to 
determine how many types of cancer are affected by solar radiation found the annual 
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number of premature deaths (1970-1994) from cancer due to lower UV-B exposures 
was 21,7000 (95% CI 20,400-23,400) for white Americans, 1400 (95% CI 1100-1600) for 
black Americans and 500 (95% CI, 400-600) for Asian Americans and other mortalities25. 
Vitamin D and GVHD 
Significant research has also been completed looking at vitamin D 
supplementation and its effect on GHVD, as GVHD is considered one of the most 
significant complications of Allo-HSCT with detrimental impact on transplant related 
mortality, overall survival, and patient quality of life25. According to research, Grade II-IV 
acute GVHD in patients range from 20-50% and chronic GVHD from 40-50% after Allo-
HSCT26,27.  In a retrospective cohort analysis, fifty-three patients’ serum 25(OH)D levels 
were looked at prior to Allo-HSCT to determine correlation with risk of GVHD27. They 
found the cumulative incidence of chronic GVHD at 2 years in patients with serum 
25(OH)D levels <25 ng/mL was 63.8% compared to 23.8% in patients with levels >25 
ng/mL (p=0.009)27. Additionally, in another retrospective analysis of 166 patients which 
evaluated 25(OH)D levels before allo-HSCT found through multivariate analysis, vitamin 
D level before transplant to be a significant independent risk factor for development of 
chronic GVHD (cGVHD) (p=0.04)28. The RR of cGVHD at two years after transplant was 
measure at 2.66 (95% CI 1.03-6.87) for 25(OH)D below 60 nmol/L compared with above 
60 nmol/L (24 ng/mL) before transplant28. 
Steroids and Allo-HSCT 
 Steroids, specifically glucocorticoids are often prescribed to patients undergoing 
Allo-HSCT as they have an inhibitory effect on specific immune responses as well as 
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suppressive effects which allow for management of inflammation or autoimmune 
disorders29. While they have many benefits for those undergoing Allo-HSCT, they have 
been proven to negatively impact bone health, causing decreased bone formation and 
bone loss, reduce bone quality, and disrupt microarchitectural integrity1. (Figure 2)  
 
Figure 2. Pathophysiology of corticosteroid-induced osteoporosis31. 
Glucocorticoid-induced osteoporosis is the most common form of secondary 
osteoporosis, and needs to be considered in patients who receive Allo-HSCT due to their 
fragile and complex health status30. Bone density declines rapidly at the beginning 
stages of using steroids and then more slowly and steadily as steroid use continues30. 
Therefore, appropriate supplementation at the beginning of steroid use is critical. The 
NOF lists glucocorticoids use of > 5 mg/d of prednisone or equivalent for > 3 months as a 
risk factor for developing osteoporosis and fractures, as well as the point to which 
supplementation of vitamin D should be initiated1. The American College of 
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Rheumatology (ACR) recommends stricter guidelines, recommending patients taking 
glucocorticoids at any dose or duration should receive vitamin D supplementation17. In 
this patient population in which steroids are often a standard form of treatment, it 
would be important to take swift action in providing proper supplementation early on in 
Allo-HSCT treatment. A prospective study of 146 patients who received Allo-HSCT found 
that at two months after transplant, more than 50% of the patients had DEXA detected 
osteoporosis, showing that subclinical bone abnormalities appear early post-HSCT32. The 
same study found that duration of steroid use was a significant risk factor for developing 
clinical bone complications as well (Hazards Ration [HR]: 1.06/month; 95% CI 1.00-1.14; 
p=0.038)32. 
Bone Mineral Density Assessment 
To better assess patient’s bone mineral density and risk of fracture, dual energy 
x-ray absorptiometry (DEXA) is considered the gold standard when determining bone 
mineral density of the lumbar spine and hip. DEXA measurements of the hip and spine is 
most often used to confirm a diagnosis of osteoporosis or predict future fracture risk1. 
Peak bone mass is achieved in early adulthood, followed by a declined which is 
accelerated in women at menopause1. NOF recommends BMD testing be performed in 
women age 65 and older and men age 70 and older. NOF continues to recommend BMD 
testing by DEXA scan in post-menopausal women and men > 50 years of age if 
prescribed short or long term glucocorticoid treatment1.  Although there is no 
consensus for optimal frequency of monitoring BMD, NOF guidelines suggest one to two 
year BMD testing after initiating medical therapy for treatment of osteoporosis and 
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every two years thereafter1. A study in 2001 assessed bone mineral density of 67 adult 
patients who received stem cell transplants. Of those patients 49% were found to have 
osteopenia and osteoporosis prior to transplant. There was also significant decrease in 
T-score when comparing bone mineral density before transplant and at six months post-
HSCT (-1.23+ 1.08 compared to -1.87+ 1.28) (p<0.001)3. This study proposed the 
demand for vitamin D is increased after Allo-HSCT, likely due to the multiple risk factors 
this patient population carries, and supplementation of both calcium and vitamin D not 
being prescribed outpatient3.  As a result, this study encourages measurement of BMD 
prior to transplant for baseline measurements. 
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CHAPTER 3: METHODS 
Participants and Study Design 
This study was a retrospective chart review of data collect from the electronic 
medical record. Inclusion criteria included age of 19 years or older and receiving an Allo-
HSCT at Nebraska Medicine from January 1, 2013 to December 31, 2014. Exclusion 
criteria included children (less than 19 years of age) and those who received Auto-HSCT. 
The Study protocol was approved by the Institutional Review Board at the University of 
Nebraska Medical Center in Omaha, Nebraska. Ninety-nine patients were eligible for 
this study. 
Data Collection 
Patients were identified with help of the Oncology/Hematology Transplant Data 
Office at the University of Nebraska Medical Center. All data was collected between two 
time points. The first time point, time of transplant, was defined as the day the patient 
underwent Allo-HSCT (this included up to 30 days prior to transplant if labs or 
information was gathered prior to the exact date of transplant). The second time point 
was at the one year follow up appointment after receiving their transplant (this included 
up to 15 months after their transplant as scheduling conflicts could have impacted their 
“one year” follow-up). Baseline characteristics were gathered at time of transplant and 
included age, sex, and race. Additional data was gathered between the time of 
transplant and one year follow-up, this included: steroids prescribed, vitamin D 
supplementation, serum 25(OH)D levels, documented falls/fractures, DEXA results, LOS, 
and, mortality.  
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Steroids 
Prescribed steroids were gathered by review of the medications tab and a 
keyword search of the term steroid within the medical record. The first classification of 
steroid use was based on the NOF criterial for vitamin D supplementation which 
specifies > 5 mg of prednisone or equivalent for >3 months for inclusion in the steroid 
group. Patients did not have to be prescribed steroids consecutively to meet 
requirements for duration of > 3 months. For example, if the patient was prescribed > 5 
mg for six non-consecutive two week periods, they met criteria to be included in the 
steroid group. All patients not meeting this criteria were placed in the non-steroid 
groups. Therefore, if a patient received high dose steroids for one month they did not 
meet criteria and were placed in the non-steroid group.  
Steroid groups were later re-categorized based on ACR recommendations for 
when vitamin D supplementation should be started. The steroid group was re-defined as 
those who received any dose/duration of steroid during the first year following 
transplant. Therefore, the patient who received high dose steroids for one month would 
be included in the steroid group. The non-steroid group consisted of those who never 
received any steroid between time of transplant and one year follow-up.  
Vitamin D Supplementation 
The primary outcome of the study was vitamin D supplementation. 
Supplementation was found via the medications tab along with keyword search for 
vitamin D in the medical chart. Use of a multivitamin was not considered as 
supplemental vitamin D. Vitamin D supplementation was categorized into yes/no 
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groups. Any dose or duration of vitamin D supplementation was placed in the yes group.  
The no group consisted of those who did not receive any vitamin D supplementation 
during time of transplant and one year follow-up. 
Serum 25(OH)D 
Serum 25(OH)D levels were collected from the “results review tab” within the 
medical record, which is the location of all laboratory results in the electronic medical 
record. All serum 25(OH)D levels were collected that occurred between date of 
transplant and one year follow-up. Therefore, if a patient had five serum 25(OH)D levels 
drawn during our study time points, all were recorded.  However only the first serum 
25(OH)D level was used in the analysis. Serum 25(OH)D levels were collected as 
continuous variables and also categorized as “adequate” and “inadequate”. Adequate 
was defined as > 30 ng/mL and inadequate was defined as < 30 ng/mL. 
GVHD 
Diagnosis of GVHD was found through keyword search in the medical chart. 
Criteria for a diagnosis of GVHD was the documentation of diagnosis within a physician’s 
note. GVHD diagnosis was categorized into yes/no groups. The yes group included acute 
and chronic GVHD and any specified type (i.e. skin, liver, gut). Those without diagnosis 
of GVHD within a physician’s note were placed in the no group.  
Falls/Fractures 
Documented falls and fractures were found through key word search in the 
medical record. Only falls/fractures documented in physician or nursing notes during 
the defined time period were gathered. Severity of fall/fracture was not collected and 
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there was no differentiation if a patient had more than one fall/fracture. To meet 
criteria for the yes group there needed to be at least one documentation in a physician 
or nurse note stating the patient had a fall/fracture. Those who did not have 
documentation of either were placed in the no group.  
DEXA scan Results 
DEXA results were collected between date of transplant and one year follow-up. 
Results were found within the “results review tab” where non-laboratory tests are 
reported. All DEXA results were collected between our two time-points. However, only 
initial DEXA scans were used for analysis. DEXA results were categorized based on the 
stated report within each scan. DEXA results at Nebraska Medicine describe bone health 
in two ways: “increased risk of fracture” and “low risk for fracture”. Therefore, these 
were the two categories used for the classification of patients in this study. Risk of 
fracture was only categorized if patient underwent DEXA scanning. Therefore, if the 
patient had documentation in the medical record of osteoporosis or osteopenia but did 
not have a DEXA scan during our time of data collection, they were categorized as 
missing data from our analysis.    
Mortality 
 Mortality was collected between time of transplant and one year follow-up and 
categorized a yes/no.  
Length of Stay 
 Length of stay was defined as the length in days during the hospitalization to 
undergo Allo-HSCT. This number was taken from day of admittance to day of discharge. 
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This information was provided by the Oncology/Hematology Transplant Data Office. 
Data Analysis 
 Descriptive statistics were calculated for all variables. Continuous variables were 
represented by means and standard deviations and categorical variables were 
represented as counts and percentages. The difference in means of the steroid vs. the 
non-steroid groups were tested using Independent Sample T-Test. The difference in 
proportion between steroid vs. the non-steroid group were evaluated with the Chi-
Square Test or the Fischer’s Exact Test, as appropriate. Multivariate analysis was 
preformed using Logistic Regression for those variables found to be significant through 
the univariate analysis. Logistic regression established an odds ratio (OR) for select 
variables of interest to determine if statistical significance remained independent of all 
other variables. A Chi-squared test was used to compare the proportion of vitamin D 
supplementation in both groups after re-categorizing steroid groups based on the ACR 
guidelines. Data analysis was preformed using IBM SPSS Statistics 23 software and p-
values of < 0.05 were considered significant.  
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CHAPTER 4: RESULTS 
Ninety-nine patients were included in the study. Forty-five were female and 54 
were male, ranging in age from 19 to 71 years of age, with a mean age of 49.7 years. The 
majority of patients were Caucasian, compiling 94.5% of the population. Fifty-eight met 
criteria for the steroid group while 41 were placed in the non-steroid group as seen in 
Table 1. 
Table 1: Steroid Groups 
Steroid vs. Non-Steroid N(%) 
Steroid (>5 mg for > 3 months) 58 (59) 
Non-Steroid  41 (41) 
Total Patients 99 
 
Baseline and clinical characteristics can be seen in Table 3 and 4 based. There 
was no significant difference between steroid groups in age, sex, and race.  
When assessing clinical characteristics based on steroid groups there was a 
statistically larger percentage of vitamin D supplementation in the steroid group 
compared to the non-steroid group (71% vs 41% respectively, p=0.04). GVHD diagnosis 
was significantly different between the groups as well; with 90% in the steroid group 
and 71% in the non-steroid group (p=0.016). Mortality was found to be statistically 
significant between groups with 51% of the non-steroid group compared to only 24% of 
those in the steroid group (p=0.005). Documented falls/fractures had a close trend to 
significance with a p-value of 0.08, with 41% of the steroid group compared to 24% of 
the non-steroid group having a documented falls or fracture. Serum 25(OH)D levels and 
DEXA results did not have p-values of significance. 
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Table 3: Continuous Variables Comparing Steroid Groups 
Variables (N) 
Groups 
Steroid (N=58) Non-Steroid (N=41) 
N Mean (S.D.) N Mean (S. D.) 
P 
value 
Age, years  58 49.3 (13.26)  41 50.3 (13.69) 0.708 
Serum 25(OH)D, ng/mL 45 31.89 (16.32)  23 30.78 (18.05)  0.799 
Length of Stay, days 58 24.48 (5.66) 41 23.90 (6.47) 0.637 
 
Table 4: Categorical Variables Comparing Steroid Groups 
 
                              Groups  
 
Steroid 
(N=58) 
Non-steroid 
(N= 41)  
Variable N % N % P Value 
Gender       
Male 30 52      24 59 
0.503 Female 28 48 17 41 
Race       
Caucasian 55 95 39 95 
1.00 Other 3 5 2 5 
Vitamin D Supplementation      
Yes 41 71 17 41  
No 17 29 24 59 0.004 
25(OH)D       
Adequate (> 30 ng/mL) 22 38 11 27  
Inadequate (< 30 ng/mL) 23 40 11 27 0.932 
GVHD Diagnosis      
Yes 52 90 29 71 
0.016 No 6 10 12 29 
Falls/Fractures      
Yes 24 41 10 24 
0.08 No 34 59 31 76 
DEXA Results      
Increased Risk for Fracture 23 40 6 15 
0.176 Low Risk for Fracture 19 33 11 27 
Mortality      
Yes 14 24 21 51 
0.005 No 44 76 20 49 
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Logistic regression was used to compare the two steroid groups and the 
variables that were found to be significant through univariate analysis. Those found to 
be significant include vitamin D supplementation, GVHD, and mortality. When 
controlling for GVHD and mortality the odds of patients in the steroid group receiving 
vitamin D supplementation are 2.952 times higher than the non-steroid group (p=0.019; 
95% CI: 1.196-7.288). The odds of individuals being diagnosed with GVHD are 4.26 times 
higher in the steroid group (p=0.014; 95% CI (1.333-13.651) when vitamin D 
supplementation and mortality are controlled. Mortality was 3.004 times more likely to 
occur in the non-steroid group comparatively when controlling for vitamin D 
supplementation and GVHD (p=0.020; 95% CI (1.187-7.606) (Table 5).  
 
Table 5: Results of the Logistic Regression Model 
Variable(s) p-value OR 95% Confidence Interval (CI) 
Vitamin D Supplementation 0.019 2.952 1.196-7.288 
GVHD 0.014 4.267 1.333-13.651 
Mortality 0.020 3.004 1.187-7.606 
 
 Additionally, an analysis was done to compare serum 25(OH)D levels between 
patients who were supplemented vitamin D and those who were not supplemented 
vitamin D. Out of 99 patients, 40 received vitamin D supplementation compared to 18 
who did not. Overall there was no significant difference found between mean serum 
25(OH)D levels between those who were supplemented and those who were not 
supplemented. 
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Table 6: Serum 25(OH)D Levels in Supplemented vs. Not Supplemented Patients 
Variables (N) 
Groups 
Supplemented 
(N=45) 
Non-Supplemented 
(N=23) 
N Mean (S.D.) N Mean (S. D.) 
P 
value 
Serum 25(OH)D (ng/mL) 45 31.84 (17.06)  23 31.13 (16.56)  0.927 
 
One final analysis was done in which steroid groups were re-categorized based 
upon ACR recommendations for vitamin D supplementation. Using these redefined 
groups, 93 individuals met criteria for the steroid group, leaving 6 in the non-steroid 
group. Of those 93 patients in the steroid group, 60% received vitamin D 
supplementation while 40% did not. Using a Fischer’s Exact test due to large discrepancy 
in group sizes, no statistical significance was found between groups (p=0.228).  
 
Table 7: Steroid groups categorized according to the ACR guidelines 
 
                              Groups  
 
Steroid 
(N=93) 
Non-steroid 
(N=6)  
Variable (Total N) N % N % 
P 
Value 
Vitamin D Supplementation      
Yes 56 60       2 33.5 
0.228 No 37 40 4 66.5 
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CHAPTER 5: DISCUSSION 
The primary outcome of this research was to determine if Allo-HSCT patients 
who received steroids > 5mg of prednisone or equivalent for > 3 months were 
supplemented with vitamin D. We found that a significantly higher proportion of those 
in the steroid group were  supplemented with vitamin D compared to the non-steroid 
group. Based on this, we can speculate that clinicians at Nebraska Medicine are aware 
of the implications of steroid use in the Allo-HSCT population and are starting a 
significant proportion of those patients on vitamin D supplementation as a result. 
However, nearly a quarter of patients remained unsupplemented. This study did not 
quantify the dose or duration of vitamin D supplementation which would have been 
beneficial to determine if patients were receiving adequate amounts during and after 
their transplant, which may be of relevance for future studies in this patient population.   
As discussed in the literature review, standard prophylactic measurements for 
bone health may not be enough to protect this patient population3. To gather more 
information on vitamin D supplementation according to steroid regimen in our 
population, we re-categorized groups based on ACR guidelines. Using these redefined 
groups, which recommend vitamin D supplementation with any dose/duration of 
steroid, it was found there was no statistical significance in vitamin D supplementation 
between the steroid and non-steroid groups. Therefore, the same proportion of patients 
were supplemented regardless of steroid use.  The sample sizes of these two groups 
were highly skewed with 93 patients in the steroid group and only 6 in the non-steroid 
group. Therefore, 94% of our population received some dose/duration of steroid 
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between our defined time points, further demonstrating the need for vitamin D 
supplementation. Allo-HSCT have increased need for vitamin D supplementation based 
on multiple factors including steroid use, previous chemotherapy, lack of sun exposure, 
and poor nutrition status1,20. While those in the non-steroid group were likely 
appropriate for supplementation, it shows that patients who did not meet criteria for > 
5mg of prednisone or equivalent for > 3 months were not being supplemented with 
vitamin D. Therefore, if a patient received high dose steroids for one month they would 
have likely not been prescribed vitamin D supplementation. A study by Petropoulou, et 
al. found that at two months’ post-transplant more than 50% of patients had DEXA 
detected osteoporosis, showing how critical early intervention is32. 
Our secondary aim was to determine what clinical outcomes were associated 
with steroid use of > 5mg of prednisone or equivalent for > 3 months. Based on review 
of literature, we hypothesized that a significant proportion Allo-HSCT patients who 
received steroids would also have inadequate serum 25(OH)D levels, documented 
falls/fractures, DEXA results demonstrating increased risk for fracture, and diagnosis of 
GVHD. 
There was no statistical difference in proportions of patients with inadequate 
serum 25(OH)D levels compared between steroid groups. There was also no significant 
difference in mean serum 25(OH)D levels when compared between steroid and non-
steroid groups (31.89+16.32 vs 30.78+18.05, p=0.799).  This could be explained by the 
fact there was a significant portion of patients in the steroid group who were 
supplemented with vitamin D, likely maintaining serum 25(OH)D levels or at least 
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preventing a decrease. Both of our mean serum 25(OH)D levels were very similar and 
met criteria for > 30 ng/mL. With that being said, out of 99 patients only 68 had initial 
serum 25(OH)D levels drawn. Of those assessed, 50% had levels categorized as 
inadequate. Overall, 33% of our patient population were never assessed for serum 
25(OH)D levels, making it difficult to accurately evaluate differences between steroid 
groups. Knowing the extensive risk factors Allo-HSCT patients carry, in the future it 
would beneficial to have more consistent testing of serum 25(OH)D levels. 
We also assessed mean serum 25(OH)D compared between supplemented and 
non-supplemented groups, as supplementation of vitamin D is a better indicator of 
serum 25(OH)D. Through this analysis, we found there was no significant difference 
between supplemented and non-supplemented groups (31.84+17.06 vs 31.13+15.56, 
p=0.927). Urbain, et al. found baseline 25(OH)D levels were 16.4+8.9 ng/mL in HSCT 
patients33. Although our levels were not collected at baseline, they do show adequate 
serum 25(OH)D levels between our two time points. It should also be noted the study 
population of Allo-HSCT patients was predominately Caucasian, thus potentially 
impacting our results as Caucasian individuals are at less risk for vitamin D deficiency 
when compared to those with darker skin tones, such as African American or Hispanic 
individuals1. 
 Falls and fractures between steroid groups were not found significant, however 
did trend in that direction (p=0.08). This finding is of interest, given our small sample 
size and the self-reported nature of this variable.  Of the 34 documented falls or 
fractures, 71% were in the steroid group compared to only 39% in the non-steroid 
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group. The LASA study found incidence of fracture was higher when serum 25(OH)D was 
lower than 30 nmol/L (12.01 ng/mL)10. They also found the lowest percentage of 
fractures occurred with serum 25(OH)D levels were above 75 nmol/L (30 ng/mL)10. 
Knowing our mean serum 25(OH)D level for the steroid group was above 30 ng/mL 
(31.89+16.32) and there was still a trend towards significance for falls and fractures, we 
could propose our patient population may benefit from having serum 25(OH)D levels 
above adequate.  
 When assessing DEXA screening between groups, 72% of those in the steroid 
group underwent DEXA screening compared to 41% of the non-steroid group. Of those 
patient’s in the steroid group, 55% were deemed to be at increased risk for fracture 
compared to only 15% in the non-steroid group (p=0.176). This finding is similar to 
Massenkeil, et al. which found 49% of HSCT patients to have osteopenia and 
osteoporosis prior to transplant3. Out of the total 99 patients who received Allo-HSCT, 
only 60% underwent DEXA scanning, leaving 40% of the population without an accurate 
look at their bone density health. These findings suggest there is need for more 
consistency when evaluating patients’ bone health. Massenkeil, et al. states it may be 
beneficial for Allo-HSCT patients to receive DEXA scans prior to transplant and one year 
after treatment has been started3. While NOF recommends BMD follow-up one year 
after initiating treatment for osteoporosis1. In this patient population, we have room for 
improvement with assessing and treating risk factors for decreased bone health. 
Although there was a significant portion of those in the steroid group being 
supplemented with vitamin D, there was also a trend towards significant for 
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falls/fractures suggesting supplementation was not adequate to raise their 25(OH)D 
levels to sufficient amounts. The lack of consistency in testing 25(OH)D levels and DEXA 
scans as well made it difficult to find meaningful results.  
 GVHD diagnosis was statistically significant between steroid groups with 90% of 
the steroid group being diagnosed with GVHD compared to 71% of the non-steroid 
group (p=0.016). This can be explained as steroids are a common treatment for GHVD 
disease. Therefore, these patients were likely diagnosed with GVHD and then started on 
steroids. As we know pre-transplant 25(OH)D, specifically levels under <25 ng/mL, are 
associate with increased risk of chronic GVHD27,28. Therefore, it may be beneficial to 
start assessing serum 25(OH)D levels prior to transplant and have their levels adequate 
before starting transplant27. 
Mortality was not a variable we had predicted to have statistical significance 
when beginning our research. However, mortality was found to be significantly higher in 
the non-steroid group compared to the steroid group, with 51% of the non-steroid 
group compared to 24% of the steroid group (p=0.005). Initially, this finding seems 
inconsistent from the information gathered from the literature review. It would have 
seemed more likely that those in the steroid group would have a higher proportion of 
mortality as they were likely being treated for complications from Allo-HSCT such as 
GVHD. However, this finding could be explained by the fact these patients who died may 
not have lived long enough to meet our requirements of the steroid group. 
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Limitations  
 Inherently, this study has limitations. As it is a retrospective chart review, bias 
may have occurred due to misclassification errors. The small sample size could have 
shown less strength in association compared with a broader sample size. Another large 
limitation to the study was the lack of consistency in drawing 25(OH)D levels along with 
DEXA scanning. More consistent information regarding these outcomes could have 
given us more detailed information to draw conclusions.  
Applications for Clinical Practice  
 Development of this study came from clinical judgement regarding the risk 
factors for decreased bone health in Allo-HSCT patients. It became apparent through 
daily observation and clinical experience that these patients had multiple factors putting 
their bone health at risk. Therefore, this study was developed in hopes to encourage use 
of vitamin D supplementation. The results from this study are to show that while many 
Allo-HSCT patients are being supplemented with vitamin D, there are inconsistencies in 
dosage and objective testing to determine if supplementation is enough to prevent a 
decline in bone health. 
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CHAPTER 6: CONCLUSION 
In conclusion, our study reports that 71% of patients who received steroids 
according to NOF guidelines received vitamin D supplementation. Overall, it is 
encouraging that over half of the patient population received vitamin D 
supplementation. However, we do not know if supplementation was adequate for this 
complex patient population due to the lack of consistency when treating and assessing 
bone health. Further research should be completed to identify adequate amounts of 
vitamin D supplementation in Allo-HSCT to maintain adequate serum 25(OH)D levels 
and prevent deteriorating bone health in this complex patient population. 
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